9月13日,同源康医药-B(02410)股价盘中大涨7.34%,最高股价达28.85港元,引起市场广泛关注。
根据公司公告,同源康医药-B已向中国证监会申请将其1.74亿股非上市股转为H股并在港交所主板流通交易。一旦申请获批并符合所有监管要求,公司的股权结构将更加市场化和透明。这有利于吸引更多投资者关注该公司,从而推动股价上涨。
另外,作为生物医药股,同源康医药-B也受益于整个行业近期的良好表现。数据显示,当天港股生物医药板块延续涨势,多只个股上涨。这也在一定程度上推动了该股价格上行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.